These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 30068751)
1. PET Imaging of Receptor Tyrosine Kinases in Cancer. Wei W; Ni D; Ehlerding EB; Luo QY; Cai W Mol Cancer Ther; 2018 Aug; 17(8):1625-1636. PubMed ID: 30068751 [TBL] [Abstract][Full Text] [Related]
2. Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Wehrenberg-Klee E; Turker NS; Heidari P; Larimer B; Juric D; Baselga J; Scaltriti M; Mahmood U J Nucl Med; 2016 Sep; 57(9):1413-9. PubMed ID: 27081168 [TBL] [Abstract][Full Text] [Related]
3. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy. Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660 [TBL] [Abstract][Full Text] [Related]
4. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Ghosh S; Marrocco I; Yarden Y Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398 [TBL] [Abstract][Full Text] [Related]
5. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198 [TBL] [Abstract][Full Text] [Related]
6. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor. Li F; Jiang S; Zu Y; Lee DY; Li Z J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912 [TBL] [Abstract][Full Text] [Related]
7. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment. Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140 [TBL] [Abstract][Full Text] [Related]
8. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329 [TBL] [Abstract][Full Text] [Related]
9. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. Altai M; Orlova A; Tolmachev V Curr Pharm Des; 2014; 20(14):2275-92. PubMed ID: 24025099 [TBL] [Abstract][Full Text] [Related]
10. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications. Camorani S; Crescenzi E; Fedele M; Cerchia L Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128 [TBL] [Abstract][Full Text] [Related]
11. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs). Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449 [TBL] [Abstract][Full Text] [Related]
12. PET imaging for tyrosine kinase inhibitor (TKI) biodistribution in mice. Fushiki H; Murakami Y; Miyoshi S; Nishimura S Methods Mol Biol; 2015; 1219():199-206. PubMed ID: 25308271 [TBL] [Abstract][Full Text] [Related]
13. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463 [TBL] [Abstract][Full Text] [Related]
14. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors. Mitrasinovic PM Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847 [TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinases as targets in cancer therapy - successes and failures. Traxler P Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099 [TBL] [Abstract][Full Text] [Related]
16. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET. Bahce I; Yaqub M; Smit EF; Lammertsma AA; van Dongen GA; Hendrikse NH Lung Cancer; 2017 May; 107():1-13. PubMed ID: 27319335 [TBL] [Abstract][Full Text] [Related]
17. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging. Li D; Zou S; Cheng S; Song S; Wang P; Zhu X Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253 [TBL] [Abstract][Full Text] [Related]
18. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship. Taruneshwar Jha K; Shome A; Chahat ; Chawla PA Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103 [TBL] [Abstract][Full Text] [Related]
20. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors. Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]